Abstract
Recent outbreaks of highly pathogenic avian influenza A virus infections (H5 and H7 subtypes) in poultry and humans have raised concerns that a new influenza pandemic will occur in near future. Currently, four antivirals have proven efficacy in the treatment and prophylaxis of influenza A infections: two M2 inhibitors (amantadine and rimantadine) and two neuraminidase inhibitors (zanamivir and oseltamivir). Early treatment with antivirals reduces the duration of symptoms and the time to recovery by one to two days. However, when antivirals are used for the treatment the antiviral resistance develops rapidly, limiting their use. There is an urgent need for research on newer antiviral agents and “universal” vaccine against influenza virus. The M2 protein from the influenza A virus forms a proton channel in the virion and is essential for infection. As a relatively conserved protein, the M2 protein seems to be a suitable candidate for development of a new generation of vaccine or antiviral agents. This review describes the role of the M2 ion channel in virus replication and the structure-function relationship of the channel.
Keywords: M2 protein, influenza virus, ion channel, antivirals
Current Pharmaceutical Design
Title: M2 Protein-A Proton Channel of Influenza A Virus
Volume: 13 Issue: 31
Author(s): Tatiana Betakova
Affiliation:
Keywords: M2 protein, influenza virus, ion channel, antivirals
Abstract: Recent outbreaks of highly pathogenic avian influenza A virus infections (H5 and H7 subtypes) in poultry and humans have raised concerns that a new influenza pandemic will occur in near future. Currently, four antivirals have proven efficacy in the treatment and prophylaxis of influenza A infections: two M2 inhibitors (amantadine and rimantadine) and two neuraminidase inhibitors (zanamivir and oseltamivir). Early treatment with antivirals reduces the duration of symptoms and the time to recovery by one to two days. However, when antivirals are used for the treatment the antiviral resistance develops rapidly, limiting their use. There is an urgent need for research on newer antiviral agents and “universal” vaccine against influenza virus. The M2 protein from the influenza A virus forms a proton channel in the virion and is essential for infection. As a relatively conserved protein, the M2 protein seems to be a suitable candidate for development of a new generation of vaccine or antiviral agents. This review describes the role of the M2 ion channel in virus replication and the structure-function relationship of the channel.
Export Options
About this article
Cite this article as:
Betakova Tatiana, M2 Protein-A Proton Channel of Influenza A Virus, Current Pharmaceutical Design 2007; 13 (31) . https://dx.doi.org/10.2174/138161207782341295
DOI https://dx.doi.org/10.2174/138161207782341295 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer’s Disease and Parkinson Disease
Current Pharmaceutical Design Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews QSAR Study on a Series of Aryl Carboxylic Acid Amide Derivatives as Potential Inhibitors of Dihydroorotate Dehydrogenase (DHODH)
Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Menopausal Transition and Chronic Diseases
Current Women`s Health Reviews Buprenorphine-Mediated Transition from Opioid Agonist to Antagonist Treatment: State of the Art and New Perspectives
Current Drug Abuse Reviews Olanzapine-Induced Reversible Pellagroid Skin Lesion
Current Drug Safety High Throughput Sonication: Evaluation for Compound Solubilization
Combinatorial Chemistry & High Throughput Screening Receptor-Independent Effects of Endocannabinoids on Ion Channels
Current Pharmaceutical Design Bedside Balance Testing in Elderly People
Current Aging Science On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Imidazole Containing Natural Products as Antimicrobial Agents: A Review
The Natural Products Journal EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Current Alzheimer Research Multiscale Molecular Dynamics of Protein Aggregation
Current Protein & Peptide Science Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Current Drug Abuse Reviews Combined Ischemic Preconditioning and Resveratrol Improved Bloodbrain Barrier Breakdown <i>via</i> Hippo/YAP/TAZ Signaling Pathway
CNS & Neurological Disorders - Drug Targets Role of Endogenous GLP-1 and its Agonists in Osteopenia and Osteoporosis: But We Little Know Until Tried
Current Diabetes Reviews Progress of Biosensors Based on Cholinesterase Inhibition
Current Medicinal Chemistry